PDT Partners’s Forte Biosciences FBRX Stock Holding History

PDT Partners’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-65	Closed	-$16K	–	723
2019 Q3	$16K	Sell	65 -67	-51%	-$102K	﹤0.01%	446
2019 Q2	$330K	Buy	+132	New	+$391K	0.02%	335

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PDT Partners's FBRX Position: Q4 2019 in Review

PDT Partners sold out of Forte Biosciences (FBRX) in Q4 2019, closing a stake of 65 shares — an estimated $16K sold.

PDT Partners first reported a position in FBRX in Q2 2019 and held it in 2 quarters. The position peaked at $330K in Q2 2019. 51 funds tracked by Wall St. Rank hold FBRX as of Q4 2019.

PDT Partners reported no remaining Forte Biosciences position as of Q4 2019 after selling out during the quarter.
PDT Partners sold 65 Forte Biosciences shares in Q4 2019, an estimated $16K.
PDT Partners first reported a position in Forte Biosciences in Q2 2019 and held it in 2 quarters.
PDT Partners's Forte Biosciences position peaked at $330K in Q2 2019.
51 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2019.

Based on PDT Partners's 13F filing for Q4 2019, filed 14 Feb 2020.